Objectives. The aim of the study was to estimate the protection level by anti-IgG to RBD S-protein of the SARS-CoV-2 delivered from natural and vaccine-induced immunity in persons who have contact with COVID-19.
Methods. Fourteen (14) persons presented a lab medical stuff and their relatives aged 19-72 years with several COVID-status (CoV-ST) who had contact with COVID-19 the last 10 days before blood collection was underwent to clinical trials.
The CoV-ST presented by 1) non-vaccinated, recovered, nV-Recover; 2) unvaccinated, non-contact, V-nC; 3) recovered and then vaccinated (hybrid), R-V (hybrid); 4) vaccinated and then infected and recovered, V-R; 5) vaccinated, now ill, |V-Ill; 6) non-vaccinated, now ill, nV-Ill. Quantitative ELISA was conducted by anti-IgG RBD S-protein SARS-CoV-2 kit in blood serum with resulting in BAU “binding antibody units” (First WHO International Standart for anti-SARS-CoV immunoglobulin (human), NIBSC code: 20/136). The estimation was performed according manual for kit and immunoassay analyser in optical density of solutions at one main wavelength of 405 nm. The Spearman’s rank correlation coefficient of nonparametric measure was used due to small numerous of cohort. Statistical analyses was calculated with GraphPad Prism 8.0.1 and Microsoft® Excel® for Microsoft 365 MSO (verse 2201 16.0.14827.20158) programs.
Results. All fourteen (14) persons who had contact with COVID-19 was immunized. Three (3) female persons aged less than 30 years had anti-IgG RBD S-protein SARS-CoV-2 in diapason from 19.2 till 230.1 BAU/mL which was infected and got ill with might-to-moderate symptoms of COVID-19 (f,34 nV-Recover; f,33 nV-Ill; f,22 V-Ill). Eleven (11) persons which was not infected and got ill 1) six (6) with R-V (hybrid) and vector technology vaccine had anti-IgG < 500 BAU/ml; 2) eight (8) persons, seven (7) of them with R-V (hybrid), vector and mRNA-technology vaccines had anti-IgG >500 BAU/ml; 3) four (4) persons with R-V (hybrid), one (1) of them had a vector technology vaccine, three (3) of them had an mRNA technology vaccine had anti-IgG > 5000 BAU/ml; 4) the highest concentration of specific anti-IgG 50,000 BAU/ml was detected in 19-year-old men with R-V (hybrid) and mRNA technology vaccine.
Conclusion. Direct moderate and moderate inverse correlation was noted between many factors which can determine an adaptive human immunity. The observe study showed a rapid immune response to neutralization of viruses in medical stuff and their relatives who had closest contact with COVID-19, aged 19 to 50 years and who previously was ill and subsequently was vaccinated triply by vector vaccine or previously was ill and then was vaccinated twice by mRNA vaccine.
Zh. Yu. Sapozhkova – MD, PhD, The International Cytology School & Innovatory Medical School, Head, Moscow, Russia; Medical Laboratory, Podolsk Diagnostic Center, Head, Podolsk, Russia. E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
G. A. Milovanova – The Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia, Resident, Moscow, Russia. E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it..
O. I. Patsap – MD, PhD, The Pathology Department of Federal Center for Brain Research and Neuro-technologies of FMBA of Russia, Head, Moscow, Russia; Scientific and Educational Resource Center for Innovative Technologies of Immunophenotyping, Digital Spatial Profiling and Ultrastructural Analysis (Molecular Morphology), Peoples? Friendship University of Russia, Researcher, Moscow, Russia. E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it..
1. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184(4):861-880. doi: 10.1016/j.cell.2021.01.007
2. Wratil PR, Stern M, Priller A, et al. Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern [published online ahead of print, 2022 Jan 28]. Nat Med. 2022/ doi:10.1038/s41591-022-01715-4
3. Moyo-Gwete T, Madzivhandila M, Makhado Z, et al. Cross-reactive neutralizing antibody responses elicited by SARS-CoV-2 501Y.V2 (B.1.351). N Engl J Med. 2021; 384(22):2161-63. doi:10.1056/NEJMc2104192
4. Reynolds CJ, Pade C, Gibbons JM, et al. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose [published online ahead of print, 2021 Apr 30]. Science. 2021; eabh1282. doi: 10.1126/science. abh1282
5. Goel RR, Apostolidis SA, Painter MM, et al. Distinct antibody and memory B cell responses in SARS-CoV-2 na?ve and recovered individuals following mRNA vaccination. Sci Immunol. 2021;6(58):eabi6950. doi:10.1126/ sciimmunol. abi6950
6. S. Crotty, Hybrid immunity. Science. 2021; 372(6549):1392-93. doi: 10.1126/science. abj2258
7. Report 49 (MRC Centre for Global Disease Analysis. Imperial College London) Available at: https:// www.imperial.ac.uk/mrc-global-infectious-disease-analysis/ covid-19/report-49-Omicron/ . Accessed: 22 Feb 2022
8. SanPiN 2.1.3684–21 “Ob utverzhdenii sanitarnykh pravil i norm SanPiN 2.1.3684–21 «Sanitarno-epidemiologicheskie trebovaniya k soderzhaniyu territorii gorodskikh i sel?skikh poselenii, k vodnym ob?ektam, pit?evoi vode i pit?evomu vodosnabzheniyu, atmosfernomu vozdukhu, pochvam, zhilym pomeshcheniyam, eksplu atatsii proizvodstvennykh, obshchestvennykh pomeshche-nii, organizatsii i provedeniyu sanitarno- protivoepidem-icheskikh (profilakticheskikh) meropriyatii”» (In Russ).
9. SanPiN 3.3686–21 “Sanitarno-epidemiologicheskie trebovaniya po profilaktike infektsionnykh boleznei”. (In Russ).
10. Instruktsiya po primeneniyu nabora reagentov dlya immunofermentnogo kolichestvennogo opredeleniya immunoglobulinov klassa G k SARS-CoV-2 (AO “Vektor-Best”). (In Russ).
11. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371(6529):eabf4063. doi:10.1126/ science.abf4063
12. Cohen KW, Linderman SL, Moodie Z, et al. Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. Preprint. medRxiv. 2021;2021.04.19.21255739. Published 2021 Jun 18. doi:10.1101/2021.04.19.21255739
13. Wang Z, Muecksch F, Schaefer-Babajew D, et al. Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year. Preprint. bioRxiv. 2021;2021.05.07.443175. Published 2021 Jun 2. doi:10.1101/2021.05.07.443175
14. Grifoni A, Sidney J, Vita R, et al. SARS-CoV-2 human T cell epitopes: adaptive immune response against COVID-19. Cell Host Microbe. 2021;29(7):1076-92. doi: 10.1016/j.chom.2021.05.010
15. Stamatatos L, Czartoski J, Wan YH, et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection [published online ahead of print, 2021 Mar 25]. Science. 2021; eabg9175. doi: 10.1126/science. abg9175
16. Painter MM, Mathew D, Goel RR, et al. Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. Immunity. 2021;54(9):2133-42.e3. doi: 10.1016/j.immuni.2021.08.001
17. Tauzin A, Nayrac M, Benlarbi M, et al. A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses. Cell Host Microbe. 2021;29(7):1137-50.e6. doi: 10.1016/ j.chom.2021.06.001
18. Bettini E, Locci M. SARS-CoV-2 mRNA Vaccines: immunological mechanism and beyond. Vaccines (Basel). 2021;9(2):147. Published 2021 Feb 12. doi: 10.3390/vaccines9020147Catherine H. Bozio, et al. Laboratory-confirmed COVID-19 among Adults hospitalized with COVID-19 – like illness with infection-induced or mrna vaccine-induced sars-cov-2 immunity – nine states, january – september // Morbidity and Mortality Weekly Report. 2021;70(44): 1539-44. Доступно по: https://www.cdc.gov/mmwr/ volumes/70/wr/pdfs/mm7044e1-H.pdf)
The article can be purchased
electronic!
PDF format
Free
DOI 10.14489/lcmp.2022.01.pp.004-016
Article type:
Research Article
Make a request
